If validated in larger cohorts, IGF/CTP score may serve as stratification tool in clinical trials, a hepatic reserve assessment tool for HCC outcomes prediction and to assist in therapy decisions. The gene discussed is IGF1; the disease is hepatocellular carcinoma.